InMode Defends Its Feminine Rejuvenation Patent Against BTL Industries' Review Request

InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, responded to the recent petition to the U.S. Patent & Trademark Office filed by BTL Industries, Inc., in which

BenzingaApr 15 19:08

InMode Responds To BTL Petition for Inter Partes Review Of Patent InMode Is Asserting Against BTL

InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, responded to the recent petition to the U.S. Patent &...

PR NewswireApr 15 19:00

InMode Is Maintained at Overweight by Barclays

InMode Is Maintained at Overweight by Barclays

Dow JonesApr 12 22:09

InMode Price Target Cut to $33.00/Share From $34.00 by Barclays

InMode Price Target Cut to $33.00/Share From $34.00 by Barclays

Dow JonesApr 12 22:09

Barclays: Maintaining the InMode (INMD.US) rating, adjusted from an increase holdings to an increase rating, and the target price was adjusted from $34.00 to $33.00.

Barclays: Maintaining the InMode (INMD.US) rating, adjusted from an increase holdings to an increase rating, and the target price was adjusted from $34.00 to $33.00.

Zhitong FinanceApr 12 22:01

Barclays Maintains Overweight on InMode, Lowers Price Target to $33

Barclays analyst Matt Miksic maintains InMode (NASDAQ:INMD) with a Overweight and lowers the price target from $34 to $33.

BenzingaApr 12 21:59